---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-011224"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2022-01-18T23:59:59+00:00"
generated_at: "2026-06-27T17:36:20.581651+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech appoints Jing Marantz as CBO, adds Rand Sutherland to board

## Summary
- Jing Marantz resigns from board effective Jan 18, 2022, to become Chief Business Officer.
- E. Rand Sutherland appointed to board same day; no committee assignments initially.
- Marantz previously SVP at Acceleron, Alnylam, Alexion; Sutherland was president of Translate Bio.
- Marantz's resignation not due to any disagreement with Krystal.
- Both appointments effective January 18, 2022.

## SEC filing metadata
- accession: 0001193125-22-011224
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2022-01-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/d294817d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-011224
- JSON: https://secwatch.observer/filing/0001193125-22-011224.json
- Plain text: https://secwatch.observer/filing/0001193125-22-011224.txt

## Key facts
- Executive change
  E. Rand Sutherland was appointed as Director at Krystal Biotech, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 13, 2022, the Board appointed E. Rand Sutherland as a member of the Board, effective January 18, 2022, to fill the vacancy created by Dr. Marantz’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm
- Executive change
  Jing Marantz was appointed as Chief Business Officer at Krystal Biotech, Inc..
  - Action: commenced
  - Role: Chief Business Officer
  source text: Dr. Marantz will continue to serve as a director of the Company until January 18, 2022, subsequent to which, she has agreed to commence a senior executive position (Chief Business Officer) at the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm
- Executive change
  Jing Marantz resigned as Director at Krystal Biotech, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 12, 2022, Jing Marantz gave notice of her resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000119312522011224/0001193125-22-011224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.